Embryonal cancers in Europe

Gemma Gatta, Andrea Ferrari, Charles A. Stiller, Guido Pastore, Gianni Bisogno, Annalisa Trama, Riccardo Capocaccia

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Embryonal cancers are a heterogeneous group of rare cancers which mainly occur in children and adolescents. The aim of the present study was to estimate the burden (incidence, prevalence, survival and proportion of cured) for the principal embryonal cancers in Europe (EU27), using population-based data from cancer registries (CRs) participating in RARECARE. We identified 3322 cases diagnosed from 1995 to 2002 (latest period for which data are available): 44% neuroblastoma, 35% nephroblastoma, 13% retinoblastoma and 6% hepatoblastoma. Very few cases of pulmonary blastoma (43 cases) and pancreatoblastoma (seven cases) were diagnosed. About 2000 new embryonal cancers were estimated every year in EU27, for an annual incidence rate of 4 per million (1.8 neuroblastoma, 1.4 nephroblastoma, and 0.5 retinoblastoma); 91% of cases occurred in patients under 15 years. Five-year relative survival for all embryonal cancers was 80% (99% retinoblastoma, 90% nephroblastoma, 71% hepatoblastoma and 68% neuroblastoma). Overall survival was lower in adolescents and adults than in those under 15 years. The cure rate was estimated at 80%. Slightly less than 40,000 persons were estimated alive in EU27 with a diagnosis of embryonal cancer in 2008. Nephroblastoma was the most prevalent (18,150 cases in EU27), followed by neuroblastoma (12,100), retinoblastoma (5200), hepatoblastoma (2700) and pulmonary blastoma (614). This is the first study to delineate the embryonal cancer burden in Europe by age, sex and European region. Survival/cure rate is generally high, but there are considerable gaps in our understanding of the natural histories of these rare diseases particularly in adults.

Original languageEnglish
Pages (from-to)1425-1433
Number of pages9
JournalEuropean Journal of Cancer
Volume48
Issue number10
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Germ Cell and Embryonal Neoplasms
Wilms Tumor
Retinoblastoma
Hepatoblastoma
Neuroblastoma
Pulmonary Blastoma
Survival
Incidence
Rare Diseases
Registries
Neoplasms
Survival Rate
Population

Keywords

  • Hepatoblastoma
  • Incidence
  • Nephroblastoma
  • Neuroblastoma
  • Pancreatoblastoma
  • Population-based study
  • Prevalence
  • Pulmonary blastoma
  • Retinoblastoma
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gatta, G., Ferrari, A., Stiller, C. A., Pastore, G., Bisogno, G., Trama, A., & Capocaccia, R. (2012). Embryonal cancers in Europe. European Journal of Cancer, 48(10), 1425-1433. https://doi.org/10.1016/j.ejca.2011.12.027

Embryonal cancers in Europe. / Gatta, Gemma; Ferrari, Andrea; Stiller, Charles A.; Pastore, Guido; Bisogno, Gianni; Trama, Annalisa; Capocaccia, Riccardo.

In: European Journal of Cancer, Vol. 48, No. 10, 07.2012, p. 1425-1433.

Research output: Contribution to journalArticle

Gatta, G, Ferrari, A, Stiller, CA, Pastore, G, Bisogno, G, Trama, A & Capocaccia, R 2012, 'Embryonal cancers in Europe', European Journal of Cancer, vol. 48, no. 10, pp. 1425-1433. https://doi.org/10.1016/j.ejca.2011.12.027
Gatta, Gemma ; Ferrari, Andrea ; Stiller, Charles A. ; Pastore, Guido ; Bisogno, Gianni ; Trama, Annalisa ; Capocaccia, Riccardo. / Embryonal cancers in Europe. In: European Journal of Cancer. 2012 ; Vol. 48, No. 10. pp. 1425-1433.
@article{de1314e4359a451c991d0ae5183610e3,
title = "Embryonal cancers in Europe",
abstract = "Embryonal cancers are a heterogeneous group of rare cancers which mainly occur in children and adolescents. The aim of the present study was to estimate the burden (incidence, prevalence, survival and proportion of cured) for the principal embryonal cancers in Europe (EU27), using population-based data from cancer registries (CRs) participating in RARECARE. We identified 3322 cases diagnosed from 1995 to 2002 (latest period for which data are available): 44{\%} neuroblastoma, 35{\%} nephroblastoma, 13{\%} retinoblastoma and 6{\%} hepatoblastoma. Very few cases of pulmonary blastoma (43 cases) and pancreatoblastoma (seven cases) were diagnosed. About 2000 new embryonal cancers were estimated every year in EU27, for an annual incidence rate of 4 per million (1.8 neuroblastoma, 1.4 nephroblastoma, and 0.5 retinoblastoma); 91{\%} of cases occurred in patients under 15 years. Five-year relative survival for all embryonal cancers was 80{\%} (99{\%} retinoblastoma, 90{\%} nephroblastoma, 71{\%} hepatoblastoma and 68{\%} neuroblastoma). Overall survival was lower in adolescents and adults than in those under 15 years. The cure rate was estimated at 80{\%}. Slightly less than 40,000 persons were estimated alive in EU27 with a diagnosis of embryonal cancer in 2008. Nephroblastoma was the most prevalent (18,150 cases in EU27), followed by neuroblastoma (12,100), retinoblastoma (5200), hepatoblastoma (2700) and pulmonary blastoma (614). This is the first study to delineate the embryonal cancer burden in Europe by age, sex and European region. Survival/cure rate is generally high, but there are considerable gaps in our understanding of the natural histories of these rare diseases particularly in adults.",
keywords = "Hepatoblastoma, Incidence, Nephroblastoma, Neuroblastoma, Pancreatoblastoma, Population-based study, Prevalence, Pulmonary blastoma, Retinoblastoma, Survival",
author = "Gemma Gatta and Andrea Ferrari and Stiller, {Charles A.} and Guido Pastore and Gianni Bisogno and Annalisa Trama and Riccardo Capocaccia",
year = "2012",
month = "7",
doi = "10.1016/j.ejca.2011.12.027",
language = "English",
volume = "48",
pages = "1425--1433",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "10",

}

TY - JOUR

T1 - Embryonal cancers in Europe

AU - Gatta, Gemma

AU - Ferrari, Andrea

AU - Stiller, Charles A.

AU - Pastore, Guido

AU - Bisogno, Gianni

AU - Trama, Annalisa

AU - Capocaccia, Riccardo

PY - 2012/7

Y1 - 2012/7

N2 - Embryonal cancers are a heterogeneous group of rare cancers which mainly occur in children and adolescents. The aim of the present study was to estimate the burden (incidence, prevalence, survival and proportion of cured) for the principal embryonal cancers in Europe (EU27), using population-based data from cancer registries (CRs) participating in RARECARE. We identified 3322 cases diagnosed from 1995 to 2002 (latest period for which data are available): 44% neuroblastoma, 35% nephroblastoma, 13% retinoblastoma and 6% hepatoblastoma. Very few cases of pulmonary blastoma (43 cases) and pancreatoblastoma (seven cases) were diagnosed. About 2000 new embryonal cancers were estimated every year in EU27, for an annual incidence rate of 4 per million (1.8 neuroblastoma, 1.4 nephroblastoma, and 0.5 retinoblastoma); 91% of cases occurred in patients under 15 years. Five-year relative survival for all embryonal cancers was 80% (99% retinoblastoma, 90% nephroblastoma, 71% hepatoblastoma and 68% neuroblastoma). Overall survival was lower in adolescents and adults than in those under 15 years. The cure rate was estimated at 80%. Slightly less than 40,000 persons were estimated alive in EU27 with a diagnosis of embryonal cancer in 2008. Nephroblastoma was the most prevalent (18,150 cases in EU27), followed by neuroblastoma (12,100), retinoblastoma (5200), hepatoblastoma (2700) and pulmonary blastoma (614). This is the first study to delineate the embryonal cancer burden in Europe by age, sex and European region. Survival/cure rate is generally high, but there are considerable gaps in our understanding of the natural histories of these rare diseases particularly in adults.

AB - Embryonal cancers are a heterogeneous group of rare cancers which mainly occur in children and adolescents. The aim of the present study was to estimate the burden (incidence, prevalence, survival and proportion of cured) for the principal embryonal cancers in Europe (EU27), using population-based data from cancer registries (CRs) participating in RARECARE. We identified 3322 cases diagnosed from 1995 to 2002 (latest period for which data are available): 44% neuroblastoma, 35% nephroblastoma, 13% retinoblastoma and 6% hepatoblastoma. Very few cases of pulmonary blastoma (43 cases) and pancreatoblastoma (seven cases) were diagnosed. About 2000 new embryonal cancers were estimated every year in EU27, for an annual incidence rate of 4 per million (1.8 neuroblastoma, 1.4 nephroblastoma, and 0.5 retinoblastoma); 91% of cases occurred in patients under 15 years. Five-year relative survival for all embryonal cancers was 80% (99% retinoblastoma, 90% nephroblastoma, 71% hepatoblastoma and 68% neuroblastoma). Overall survival was lower in adolescents and adults than in those under 15 years. The cure rate was estimated at 80%. Slightly less than 40,000 persons were estimated alive in EU27 with a diagnosis of embryonal cancer in 2008. Nephroblastoma was the most prevalent (18,150 cases in EU27), followed by neuroblastoma (12,100), retinoblastoma (5200), hepatoblastoma (2700) and pulmonary blastoma (614). This is the first study to delineate the embryonal cancer burden in Europe by age, sex and European region. Survival/cure rate is generally high, but there are considerable gaps in our understanding of the natural histories of these rare diseases particularly in adults.

KW - Hepatoblastoma

KW - Incidence

KW - Nephroblastoma

KW - Neuroblastoma

KW - Pancreatoblastoma

KW - Population-based study

KW - Prevalence

KW - Pulmonary blastoma

KW - Retinoblastoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84862016990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862016990&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2011.12.027

DO - 10.1016/j.ejca.2011.12.027

M3 - Article

VL - 48

SP - 1425

EP - 1433

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 10

ER -